The Glaucoma 360 Annual Gala showcases the visionaries and catalysts who share Glaucoma Research Foundation's mission to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
Glaucoma Research Foundation (GRF) marked World Glaucoma Week today by announcing $1.6 million dollars in research grants.
“Charlie Wilmoth and his family have been actively involved with Glaucoma Research Foundation for many years,” said Andrew G. Iwach, MD, Chair of the Glaucoma Research Foundation Board of Directors. “His passion for educating the public about glaucoma and research to find a cure is truly inspiring.”
Glaucoma Research Foundation, the nation’s most experienced foundation dedicated solely to glaucoma research and education, recently elected two new members to serve on its Board of Directors: Monica L. Vetter, PhD, and Ruth D. Williams, MD.
Glaucoma is a leading cause of blindness worldwide. Vision loss from glaucoma occurs when axons in the optic nerve become damaged and can no longer carry visual information to the brain.
I've heard that glaucoma is caused by high eye pressure, and that left untreated glaucoma can cause blindness. At what pressure will I go blind?
Over 3 million Americans and over 60 million people worldwide have glaucoma. Experts estimate that half of them don’t know they have it. Learn more about this sight-stealing disease and what you can do.
Glaucoma Research Foundation will host the fifth annual Glaucoma 360 New Horizons Forum on January 29, 2016 at the historic Palace Hotel in San Francisco.
Honorees at the 10th Annual Gala will be: Charlot and Dennis Singleton, James Wise, MD, and Masashi Oka. The Gala will take place on January 28, 2016 at San Francisco’s historic Palace Hotel.
For his research project to determine whether therapies can be designed to modulate the immune system to prevent vision loss and blindness in glaucoma patients, Stuart J. McKinnon, MD, PhD was awarded the 2016 Shaffer Prize for Innovative Glaucoma Research.
Glaucoma Research Foundation marked World Glaucoma Week today by announcing $1.3 million in research grants to investigators at prestigious universities and medical research centers nationwide.
The Glaucoma Research Foundation honored Charlot and Dennis Singleton (Atherton, CA), James B. Wise, MD, and Masashi Oka (Executive Chairman emeritus for MUFG Union Bank), at the Glaucoma 360 Annual Gala on January 28, 2016 at San Francisco’s historic Palace Hotel.
Stem cells may have the potential to protect the optic nerve from further damage and slow the progression of vision loss due to glaucoma. Stem cells may also have the potential to replace ocular tissues that have degenerated in eyes with glaucoma.
Scientists in Australia have discovered new genetic areas linked to an increased risk of angle-closure glaucoma. Also called narrow-angle glaucoma, this form is much less common than open-angle glaucoma and is a very different form because the eye pressure usually rises very quickly.
Stem cells are undifferentiated cells which have the potential to develop into many different types of specialized tissues.
Safe driving requires clear central vision and adequate peripheral vision. Glaucoma typically leads to constriction of the visual field, sparing the central vision.
A recent study suggests that a diet that includes plenty of green, leafy vegetables may lower the risk of glaucoma.
What causes vision loss in glaucoma? There are two common answers that at first may seem disparate: the first is pressure, as in elevated ocular pressure, and the second is damage to the optic nerve, which is the structure that sends visual information to the brain. Both answers are correct.
This unique three-day event dedicated to highlighting innovation in glaucoma kicks off with a fundraising Gala, followed by the New Horizons Forum and educational symposia for Clinicians.
The Catalyst Award, Glaucoma Research Foundation’s highest honor, will be presented to Eugene de Juan, Jr., MD, Founder and Vice-Chairman of ForSight Labs and the Jean Kelly Stock Distinguished Professor of Ophthalmology at the University of California San Francisco, in recognition of his outstanding leadership and commitment to advancing ophthalmology.
January is National Glaucoma Awareness Month -- Learn about this sight-stealing eye disease and how to spread the word and help speed the cure.
One way to reduce vision loss from glaucoma is to make sure your family members understand that they are at increased risk - if you have glaucoma.
The Glaucoma 360 Annual Gala at San Francisco’s historic Palace Hotel honored leaders in glaucoma research innovation and visionary volunteers helping to raise awareness.
The Shaffer Prize is awarded annually by Glaucoma Research Foundation to recognize a researcher whose project best exemplifies the pursuit of innovative ideas in the quest to cure glaucoma.
Scientific research builds its own momentum as one discovery triggers another, building an ongoing wave of unexpected possibilities. In the world of glaucoma, such a surge began when advances in stem cell research opened doors experts had never imagined.
It is no secret that the issues associated with current glaucoma medications can be problematic. Systemic medications carry the risk of side effects, while the current medical treatment of choice, eye drops, has its own drawbacks. Studies show that half of patients stop taking their prescription glaucoma eye drops after a year, leaving them vulnerable to vision loss
Glaucoma Research Foundation (GRF) marked World Glaucoma Week today by announcing $1.3 million in research grants. Glaucoma Research Foundation is funding eight researchers at prestigious universities and medical research centers with one-year Shaffer Grants, as well as the four principal investigators engaged in the multi-year “Catalyst for a Cure” biomarker initiative.
Connecting pieces of information by finding a common thread often takes glaucoma researchers in unexpected directions. Zinc is one such thread that joined together different experts at Boston Children’s Hospital and Harvard Medical School.
Glaucoma in developing countries represents a significant health crisis. The great majority of people in developing countries aren’t ever tested for glaucoma, so diagnosis and treatment are rare. And if they are diagnosed, they often can’t pay for medication, assuming medications are available.
Glaucoma Research Foundation has announced the most ambitious fundraising effort in its history with the public launch of The Cure is in Sight Campaign at its Annual Meeting and Dinner last week in San Francisco.
Glaucoma Research Foundation, the nation’s most experienced foundation dedicated solely to glaucoma research and education, recently elected John G. Flanagan, PhD, FCOptom to its Board of Directors.
The 4-star rating is Charity Navigator’s highest rating, indicating that “Glaucoma Research Foundation exceeds industry standards and outperforms most charities in its Cause.”
Traditional eye drops, while the go-to medication option for glaucoma patients, still have lots of room for improvement. Dosing regimens can be difficult to manage or remember, irritation or redness can occur, and much of the medication gets blinked away before reaching the eye. Because of these challenges, researchers are working to make taking glaucoma medication easier.
Research scientists interested in applying for a 1-year, $40,000 Shaffer Grant should visit the Glaucoma Research Foundation website.
At present, the only FDA approved method of treating glaucoma is to lower eye pressure; this slows the progression of glaucomatous optic nerve damage but does not completely halt it, and certainly does not regenerate damaged nerve tissue.
People with obstructive sleep apnea syndrome (OSAS), a disorder characterized by repetitive episodes of paused and shallow breathing during sleep, are approximately ten times more likely to develop glaucoma.
Dr. Jeff Goldberg: I really want to thank the Glaucoma Research Foundation. Obviously, what we’re going to talk about today would not come to fruition without the support of the Glaucoma Research Foundation and of course, all of their supporters.
Glaucoma Research Foundation will host the 7th Annual Glaucoma 360 from February 8th to February 10th in San Francisco. This signature three-day event highlights innovation in glaucoma to ensure patients have access to the latest and most effective treatment options.
The Catalyst Award, Glaucoma Research Foundation's highest honor, will be presented to Thomas W. Burns, President and CEO of Glaukos Corporation (Laguna Hills, CA), in recognition of his remarkable leadership and commitment to the development of innovative glaucoma treatments.
The Shaffer Prize, presented annually by Glaucoma Research Foundation, recognizes a researcher whose project best exemplifies the pursuit of innovative ideas in the quest to better understand glaucoma.
Glaucoma Research Foundation (GRF) announced today $720,000 in annual research grants to support 12 investigators at prestigious universities across the United States.
GRF has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure.
GRF has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure.
If you have glaucoma, you're wondering: What will my new ophthalmologist need to hit the ground running and manage my disease? In my experience, to make a smooth transition to optimal care, the most important thing you can do is create a personal Glaucoma Data Portfolio
Glaucoma Research Foundation, a national non-profit organization dedicated to finding a cure for glaucoma, today announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also be applicable to other neurodegenerative diseases, including Alzheimer's disease.
Glaucoma Research Foundation (GRF) is pleased to announce the addition of Meredith L. Gale as the organization's new Director of Development. Meredith joins the GRF team to manage donor stewardship programs as well as major and planned giving strategies. Additionally, she will coordinate the GRF Ambassadors program, a national leadership group of glaucoma doctors dedicated to improving access to patient education.
Glaucoma is a disease where the optic nerve gets damaged and the main risk factor is elevated eye pressure (also called intraocular pressure, IOP). The only treatment is to lower the IOP.
glaucoma does affect reading. Why? First, while glaucoma does affect peripheral vision, it also affects central vision. Glaucoma patients with moderate or severe disease often describe looking through a fog which extends into their central vision.
Currently, all therapy for glaucoma is directed at lowering eye pressure, but the fundamental problem in glaucoma is the degeneration of the optic nerve fibers necessary for vision.
What is Normal-tension glaucoma? Also called low-tension or normal-pressure glaucoma, normal-tension glaucoma (NTG) is a condition in which the optic nerve is damaged without eye pressure exceeding the average range (usually between 12-21mm Hg).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right